Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment

Breast Cancer Research

Volumn 11, Issue 4, 2009, Pages

  Bollet, Marc A ^a   Savignoni, Alexia ^a   De Koning, Leanne ^b   Tran Perennou, Carine ^a   Barbaroux, Catherine ^a   Degeorges, Armelle ^a   Sigal Zafrani, Brigitte ^a   Almouzni, Geneviève ^b   Cottu, Paul ^a   Salmon, Rémy ^a   Servant, Nicolas ^a,c,d   Fourquet, Alain ^a   de Cremoux, Patricia ^a  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c INSERM U900   (France)

^d PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE; CYCLIN E; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR BETA; FLUOROURACIL; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSCRIPTION FACTOR GATA 3; ESTROGEN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARCINOMA IN SITU; CONSERVATIVE TREATMENT; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; CARCINOMA; COMPARATIVE STUDY; ENZYMOLOGY; FOLLOW UP; GENETIC ASSOCIATION; GENETICS; NEOPLASM; PHYSIOLOGY; PREMENOPAUSE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SEGMENTAL MASTECTOMY; SIGNAL TRANSDUCTION; TUMOR RECURRENCE;

ADULT; AGE FACTORS; AROMATASE; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; HUMANS; MASTECTOMY, SEGMENTAL; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; PREMENOPAUSE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77449083760     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2343     Document Type: Article

References (61)

1. Temple WJ, Russell ML, Parsons LL, Huber SM, Jones CA, Bankes J, Eliasziw M. Conservation surgery for breast cancer as the preferred choice: a prospective analysis. J Clin Oncol 2006, 24:3367-3373. 10.1200/JCO.2005.02.7771, 16849750.
2. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 366:2087-2106.
3. Engel J, Kerr J, Schlesinger-Raab A, Sauer H, Holzel D. Quality of life following breast-conserving therapy or mastectomy: results of a 5-year prospective study. Breast J 2004, 10:223-231. 10.1111/j.1075-122X.2004.21323.x, 15125749.
4. Moyer A. Psychosocial outcomes of breast-conserving surgery versus mastectomy: a meta-analytic review. Health Psychol 1997, 16:284-298. 10.1037/0278-6133.16.3.284, 9152708.
5. Vrieling C, Collette L, Fourquet A, Hoogenraad WJ, Horiot JC, Jager JJ, Bing Oei S, Peterse HL, Pierart M, Poortmans PM, Struikmans H, Bogaert W, Bartelink H. Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients?. Eur J Cancer 2003, 39:932-944. 10.1016/S0959-8049(03)00123-0, 12706362.
6. Bollet MA, Sigal-Zafrani B, Mazeau V, Savignoni A, de la Rochefordiere A, Vincent-Salomon A, Salmon R, Campana F, Kirova YM, Dendale R, Fourquet A. Age remains the first prognostic factor for loco-regional breast cancer recurrence in young (< 40 years) women treated with breast conserving surgery first. Radiother Oncol 2007, 82:272-280. 10.1016/j.radonc.2007.01.001, 17287037.
7. Oh JL, Bonnen M, Outlaw ED, Schechter NR, Perkins GH, Strom EA, Babiera G, Oswald MJ, Allen PK, Thames HD, Buchholz TA. The impact of young age on locoregional recurrence after doxorubicin-based breast conservation therapy in patients 40 years old or younger: how young is "young"?. Int J Radiat Oncol Biol Phys 2006, 65:1345-52.
8. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993, 15:17-35.
9. Chen JQ, Brown TR, Yager JD. Mechanisms of hormone carcinogenesis: evolution of views, role of mitochondria. Adv Exp Med Biol 2008, 630:1-18.
10. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354:270-282. 10.1056/NEJMra050776, 16421368.
11. Nolan T, Hands RE, Bustin SA. Quantification of mRNA using real-time RT-PCR. Nat Protoc 2006, 1:1559-1582. 10.1038/nprot.2006.236, 17406449.
12. Larionov A, Krause A, Miller W. A standard curve based method for relative real time PCR data processing. BMC Bioinformatics 2005, 6:62. 1274258, 15780134, 10.1186/1471-2105-6-62.
13. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours. 2002, New York: Wiley-Liss.
14. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer, I: the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410. 10.1111/j.1365-2559.1991.tb00229.x, 1757079.
15. Vincent-Salomon A, Rousseau A, Jouve M, Beuzeboc P, Sigal-Zafrani B, Freneaux P, Rosty C, Nos C, Campana F, Klijanienko J, Al Ghuzlan A, Sastre-Garau X. Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 2004, 40:1502-1508. 10.1016/j.ejca.2004.03.014, 15196533.
16. Balaton AL, Coindre JM, Collin F, Ettore F, Fiche M, Jacquemier J, Le Doussal V, Mandard AM, Mathieu MC, Migeon C, Simony-Lafontaine J, Treilleux I, Verriele V, Vilain MO, Zafrani B. [Recommendations for the immunohistochemical evaluation of hormone receptors on paraffin sections of breast cancer: Study Group on Hormone Receptors using Immunohistochemistry FNCLCC/AFAQAP: National Federation of Centres to Combat Cancer/French Association for Quality Assurance in Pathology]. Ann Pathol 1996, 16:144-148.
17. Antonini N, Jones H, Horiot JC, Poortmans P, Struikmans H, Van den Bogaert W, Barillot I, Fourquet A, Jager J, Hoogenraad W, Collette L, Pierart M, Hart G, Bartelink H. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. Radiother Oncol 2007, 82:265-271. 17126434, 10.1016/j.radonc.2006.09.014.
18. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Bogaert W, Barillot I, Fourquet A, Borger J, Jager J, Hoogenraad W, Collette L, Pierart M. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001, 345:1378-1387. 10.1056/NEJMoa010874, 11794170.
19. de Cremoux P, Bieche I, Tran-Perennou C, Vignaud S, Boudou E, Asselain B, Lidereau R, Magdelenat H, Becette V, Sigal-Zafrani B, Spyratos F. Inter-laboratory quality control for hormone-dependent gene expression in human breast tumors using real-time reverse transcription-polymerase chain reaction. Endocr Relat Cancer 2004, 11:489-495. 10.1677/erc.1.00808, 15369450.
20. de Cremoux P, Jourdan-Da-Silva N, Couturier J, Tran-Perennou C, Schleiermacher G, Fehlbaum P, Doz F, Mosseri V, Delattre O, Klijanienko J, Vielh P, Michon J. Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr Blood Cancer 2007, 48:311-317. 10.1002/pbc.20853, 16609945.
21. dbEST, htgs and nr data bases. , http://blast.ncbi.nlm.nih.gov
22. Cox DR, Oakes D. Analysis of Survival Data. 1984, London: Chapman & Hall.
23. Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, Veltkamp SC, Nuyten DS, Bartelink H, Vijver MJ. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 2009, 15:4181-90. 10.1158/1078-0432.CCR-08-2644, 19470741.
24. Nuyten DS, Kreike B, Hart AA, Chi JT, Sneddon JB, Wessels LF, Peterse HJ, Bartelink H, Brown PO, Chang HY, Vijver MJ. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res 2006, 8:R62. 1779489, 17069664, 10.1186/bcr1614.
25. Holli K, Isola J. Effect of age on the survival of breast cancer patients. Eur J Cancer 1997, 33:425-428. 10.1016/S0959-8049(97)89017-X, 9155527.
26. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S, Ohuchi N, Sasano H. Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Res 2007, 67:3945-3954. 10.1158/0008-5472.CAN-06-3105, 17440110.
27. Santner SJ, Pauley RJ, Tait L, Kaseta J, Santen RJ. Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab 1997, 82:200-208. 10.1210/jc.82.1.200, 8989259.
28. Yue W, Wang JP, Hamilton CJ, Demers LM, Santen RJ. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res 1998, 58:927-932.
29. Chen S, Zhou D, Okubo T, Kao YC, Yang C. Breast tumor aromatase: functional role and transcriptional regulation. Endocr Relat Cancer 1999, 6:149-156. 10.1677/erc.0.0060149, 10731103.
30. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR. Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous human breast tissues. J Steroid Biochem Mol Biol 2000, 72:23-27. 10.1016/S0960-0760(00)00040-6, 10731634.
31. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003, 348:2431-2442. 10.1056/NEJMra023246, 12802030.
32. Wang Y, Ye L, Leung LK. A positive feedback pathway of estrogen biosynthesis in breast cancer cells is contained by resveratrol. Toxicology 2008, 248:130-135. 10.1016/j.tox.2008.03.017, 18462857.
33. Galmiche G, Corvaisier S, Kottler ML. Aromatase gene expression and regulation in the female rat pituitary. Ann N Y Acad Sci 2006, 1070:286-292. 10.1196/annals.1317.028, 16888180.
34. Pauley RJ, Santner SJ, Tait LR, Bright RK, Santen RJ. Regulated CYP19 aromatase transcription in breast stromal fibroblasts. J Clin Endocrinol Metab 2000, 85:837-846. 10.1210/jc.85.2.837, 10690899.
35. Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y, Wu X, Kobayashi S, Iwase H. Quantitative determination, by real-time reverse transcription polymerase chain reaction, of aromatase mRNA in invasive ductal carcinoma of the breast. Breast Cancer Res 2003, 5:R250-R256. 314416, 14580261, 10.1186/bcr657.
36. Miller WR, Hawkins RA, Forrest AP. Significance of aromatase activity in human breast cancer. Cancer Res 1982, 42:3365s-3368s.
37. Silva MC, Rowlands MG, Dowsett M, Gusterson B, McKinna JA, Fryatt I, Coombes RC. Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer Res 1989, 49:2588-2591.
38. Evans TR, Rowlands MG, Silva MC, Law M, Coombes RC. Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer. J Steroid Biochem Mol Biol 1993, 44:583-587. 10.1016/0960-0760(93)90263-V, 8476770.
39. Sasano H, Frost AR, Saitoh R, Harada N, Poutanen M, Vihko R, Bulun SE, Silverberg SG, Nagura H. Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. J Clin Endocrinol Metab 1996, 81:4042-4046. 10.1210/jc.81.11.4042, 8923858.
40. Salhab M, Reed MJ, Al Sarakbi W, Jiang WG, Mokbel K. The role of aromatase and 17-beta-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer. Breast Cancer Res Treat 2006, 99:155-162. 10.1007/s10549-006-9198-8, 16541304.
41. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 58566, 11553815, 10.1073/pnas.191367098.
42. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423. 166244, 12829800, 10.1073/pnas.0932692100.
43. Bertucci F, Houlgatte R, Benziane A, Granjeaud S, Adelaide J, Tagett R, Loriod B, Jacquemier J, Viens P, Jordan B, Birnbaum D, Nguyen C. Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet 2000, 9:2981-2991. 10.1093/hmg/9.20.2981, 11115842.
44. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J, Thurlimann B, Rudenstam CM, Lindtner J, Crivellari D, Cortes-Funes H, Simoncini E, Werner ID, Coates AS, Goldhirsch A. Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?. Lancet 2000, 355:1869-1874. 10.1016/S0140-6736(00)02292-3, 10866443.
45. Mehra R, Varambally S, Ding L, Shen R, Sabel MS, Ghosh D, Chinnaiyan AM, Kleer CG. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res 2005, 65:11259-11264. 10.1158/0008-5472.CAN-05-2495, 16357129.
46. Oh DS, Troester MA, Usary J, Hu Z, He X, Fan C, Wu J, Carey LA, Perou CM. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol 2006, 24:1656-1664. 10.1200/JCO.2005.03.2755, 16505416.
47. Voduc D, Cheang M, Nielsen T. GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value. Cancer Epidemiol Biomarkers Prev 2008, 17:365-373. 10.1158/1055-9965.EPI-06-1090, 18268121.
48. Zhao C, Dahlman-Wright K, Gustafsson JA. Estrogen receptor beta: an overview and update. Nucl Recept Signal 2008, 6:e003. 2254331, 18301783.
49. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet 2002, 111:115-127. 10.1007/s00439-002-0783-6, 12189484.
50. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG, Nevins JR, Potti A, Blackwell KL. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008, 26:3324-3330. 10.1200/JCO.2007.14.2471, 18612148.
51. Hartley MC, McKinley BP, Rogers EA, Kalbaugh CA, Messich HS, Blackhurst DW, Lokey JS, Trocha SD. Differential expression of prognostic factors and effect on survival in young (< or = 40) breast cancer patients: a case-control study. Am Surg 2006, 72:1189-1194. discussion 1194-1185..
52. Agrup M, Stal O, Olsen K, Wingren S. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 2000, 63:23-29. 10.1023/A:1006498721508, 11079156.
53. Hamelers IH, Steenbergh PH. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 2003, 10:331-345. Review., 12790794, 10.1677/erc.0.0100331.
54. Hayashi S, Sakamoto T, Inoue A, Yoshida N, Omoto Y, Yamaguchi Y. Estrogen and growth factor signaling pathway: basic approaches for clinical application. J Steroid Biochem Mol Biol 2003, 86:433-442. 10.1016/S0960-0760(03)00354-6, 14623541.
55. Nicholson RI, Gee JM, Knowlden J, McClelland R, Madden TA, Barrow D, Hutcheson I. The biology of antihormone failure in breast cancer. Breast Cancer Res Treat 2003, 80(suppl 1):S29-S34. discussion S35., 10.1023/A:1025467500433, 14535532.
56. Elkhuizen PH, Voogd AC, Broek LC, Tan IT, van Houwelingen HC, Leer JW, Vijver MJ. Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. Int J Radiat Oncol Biol Phys 1999, 45:73-83.
57. Andre F, Khalil A, Slimane K, Massard C, Mathieu MC, Vignot S, Assi H, Delaloge S, Spielmann M. Mitotic anthracycline-based chemotherapy in patients with early breast cancer. J Clin Oncol 2005, 23:2996-3000. 10.1200/JCO.2005.08.046, 15860855.
58. Polo SE, Theocharis SE, Klijanienko J, Savignoni A, Asselain B, Vielh P, Almouzni G. Chromatin assembly factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Cancer Res 2004, 64:2371-2381. 10.1158/0008-5472.CAN-03-2893, 15059888.
59. Nimeus-Malmstrom E, Ritz C, Eden P, Johnsson A, Ohlsson M, Strand C, Ostberg G, Ferno M, Peterson C. Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. Eur J Cancer 2006, 42:2729-2737. 10.1016/j.ejca.2006.06.031, 17023159.
60. Koscielny S, Michiels S, Boige V, Hill C. Validation of microarray data by quantitative reverse-transcriptase polymerase chain reaction. J Clin Oncol 2005, 23:9439-9440. author reply 9440., 10.1200/JCO.2005.04.1004, 16361648.
61. Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, Foekens JA, Zhang Y, Wang Y, Marcom K, Marks JR, Mukherjee S, Nevins JR, Blackwell KL, Potti A. Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS ONE 2008, 3:e1373. 2148101, 18167534, 10.1371/journal.pone.0001373.